SITC Recap: IsoPlexis Demonstrates How Single-Cell Functional Proteomics Reveals Key Insights into Cell Behavior to Improve Cancer Therapies

IsoPlexis recently attended the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), the largest conference based solely on immunotherapy, which gathers leaders from academia, regulatory and government agencies, and industry representatives to highlight the latest advancements in the immunotherapy space.

Attendees at SITC had the opportunity to interact with the IsoSpark, IsoPlexis’ benchtop instrument for functional proteomic analysis, and experience first-hand how the intuitive touchscreen interface and effortless automation makes it simple to generate functional proteomic data from individual cells or bulk samples, all with an automated workflow that eliminates tedious steps. IsoPlexis’ single-cell functional proteomics has been used across a number of applications, including cancer immunology, to reveal subsets of highly polyfunctional cells, which can be predictive of patient response and disease progression.

Single-Cell Functional Proteomics Helps Development of Cell Therapies

Among those exhibiting in the poster sessions, one cell therapy development group shared preliminary preclinical research on the characterization of a novel CAR-T candidate for potential “off-the-shelf” applications. The study employed IsoPlexis’ single-cell proteomics to functionally profile the CAR-T cells, designed to target a ligand found on several types of tumors. These early-stage insights into function helped characterize their candidate for further testing.

In a second study presented at the poster session, researchers used IsoPlexis’ single-cell functional analysis to evaluate allogeneic CAR-T candidates targeted to prostate cancer cells. In this study, polyfunctionality was used to evaluate the effects of CAR-T cell alterations, identifying potential for further preclinical and clinical investigation. Both posters demonstrate how single-cell analysis can help to provide actionable insights into CAR-T product characteristics, driving development of more effective cell therapies.

The functional data generated from IsoPlexis’ single-cell platform allows researchers to better understand product potency, predict therapeutic response, and reveal mechanisms of relapse and resistance. IsoPlexis’ unique metrics of functionality have helped to guide cancer therapy product development, and leaders in the immunotherapy space continue to utilize IsoPlexis’ Single-Cell Secretome solution to gain actionable insights into therapeutic product characteristics to drive development of more effective therapies.

Using Single-Cell Functionality to Improve Cancer Treatments

IsoPlexis’ single-cell functional proteomics has been used to evaluate a variety of novel cancer treatments, including cell therapies. With the automated workflow and integrated data analysis, IsoPlexis is helping researchers to identify key quality metrics and better understand cell function, leading to improved therapies, novel targets, and better outcomes for cancer treatment.

If you missed IsoPlexis at SITC, we’ll be exhibiting at ASH in New Orleans from December 10-13. Stop by our booth to see our innovative platform and discuss how single-cell functional analysis can help your research.

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.